Physician profile
Robert Kantor
NPI 1790774180
$13,112.80
in general payments reported to CMS, 2019-2025
61 companies · $61.56 in 2025
The $61.56 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,731 · 2020: $6,232 · 2021: $3,332 · 2022: $1,346 · 2023: $262 · 2024: $150 · 2025: $61.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402 · Education: $71.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.43 |
| Education | $71.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,920.96 | 2019-2025 | Enhertu |
| Genzyme Corporation | $1,462.40 | 2019-2023 | |
| Seagen INC. | $1,369.81 | 2020-2022 | |
| Amgen INC. | $320.95 | 2019-2022 | |
| Genentech USA, INC. | $296.77 | 2019-2022 | |
| Janssen Biotech, INC. | $277.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $245.03 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $232.79 | 2019-2022 | |
| Pfizer INC. | $212.05 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.06 | 2019-2023 | Ninlaro, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $134.99 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $131.17 | 2019-2022 | |
| Celgene Corporation | $107.77 | 2019-2023 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $99.91 | 2019-2022 | |
| Exelixis INC. | $93.76 | 2019-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kantor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.